APA (7th ed.) Citation

MH, W., LW, M., DE, F., ME, W., EC, K., HE, P., . . . EK, C. (2003). Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clinical Therapeutics, 25(6), 1700. https://doi.org/10.1016/s0149-2918(03)80164-9

Chicago Style (17th ed.) Citation

MH, Weisman, et al. "Efficacy, Pharmacokinetic, and Safety Assessment of Adalimumab, a Fully Human Anti-tumor Necrosis Factor-alpha Monoclonal Antibody, in Adults with Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Pilot Study." Clinical Therapeutics 25, no. 6 (2003): 1700. https://doi.org/10.1016/s0149-2918(03)80164-9.

MLA (9th ed.) Citation

MH, Weisman, et al. "Efficacy, Pharmacokinetic, and Safety Assessment of Adalimumab, a Fully Human Anti-tumor Necrosis Factor-alpha Monoclonal Antibody, in Adults with Rheumatoid Arthritis Receiving Concomitant Methotrexate: A Pilot Study." Clinical Therapeutics, vol. 25, no. 6, 2003, p. 1700, https://doi.org/10.1016/s0149-2918(03)80164-9.